Aromatase activity and bone loss

Advances in Clinical Chemistry

Volumn 54, Issue , 2011, Pages 129-164

  Gennari, Luigi ^a   Merlotti, Daniela ^a   Nuti, Ranuccio ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE; ESTROGEN;

ANIMAL; ANTIBODY SPECIFICITY; BIOSYNTHESIS; BONE; BONE DENSITY; BONE REMODELING; BOOK; FEMALE; GENETICS; HUMAN; MALE; METABOLISM; OSTEOPOROSIS; PHYSIOLOGY;

ANIMALS; AROMATASE; BONE AND BONES; BONE DENSITY; BONE REMODELING; ESTROGENS; FEMALE; HUMANS; MALE; ORGAN SPECIFICITY; OSTEOPOROSIS;

EID: 79953857498     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-387025-4.00006-6     Document Type: Book

References (180)

1. Riggs B.L., Khosla S., Melton L.J. Sex steroids and the construction and conservation of the adult skeleton. Endocr. Rev. 2002, 23:279-302.
2. Khosla S. Update on estrogens and the skeleton. J. Clin. Endocrinol. Metab. 2010, 95:3569-3577.
3. Khosla S., Melton L.J., Riggs B.L. Clinical review 144: estrogen and the male skeleton. J. Clin. Endocrinol. Metab. 2002, 87:1443-1450.
4. Gennari L., Khosla S., Bilezikian J.P. Estrogen and fracture risk in men. J. Bone Miner. Res. 2008, 23:1548-1551.
5. Gennari L., Khosla S., Bilezikian J.P. Estrogen effects on bone in the male skeleton. Principles of Bone Biology 2008, 1801-1818. Elsevier Academic Press, San Diego, CA. third ed. J.P. Bilezikian, L.G. Raisz, J. Martin (Eds.).
6. Vandenput L., Ohlsson C. Estrogens as regulators of bone health in men. Nat. Rev. Endocrinol. 2009, 5:437-443.
7. Clarke B.L., Khosla S. Androgens and bone. Steroids 2009, 74:296-305.
8. Simpson E.R., Mahendroo M.S., Means G.D., et al. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocrinol. Rev. 1994, 15:342-355.
9. Simpson E.V., Davis S.R. Minireview: aromatase and the regulation of estrogen biosynthesis - some new perspectives. Endocrinology 2001, 142:4589-4594.
10. Santen R.J., Brodie H., Simpson E.R., Siiteri P.K., Brodie A. History of aromatase: saga of an important biological mediator and therapeutic target. Endocr. Rev. 2009, 30:343-375.
11. Steinach E., Kun H. Transformation of male sex hormones into a substance with the action of a female hormone. Lancet 1937, 133:845.
12. Pasanen M., Pelkonen O. Solubilization and partial purification of human placental cytochromes P-450. Biochem. Biophys. Res. Commun. 1981, 103:1310-1317.
13. Kellis J.T., Vickery L.E. Purification and characterization of human placental aromatase cytochrome P-450. J. Biol. Chem. 1987, 262:4413-4420.
14. Nelson L.R., Bulun S.E. Estrogen production and action. J. Am. Acad. Dermatol. 2001, 45:S116-S124.
15. Simpson E.R. Sources of estrogen and their importance. J. Steroid Biochem. Mol. Biol. 2003, 86:225-230.
16. Grodin J.M., Siiteri P.K., MacDonald P.C. Source of estrogen production in postmenopausal women. J. Clin. Endocrinol. Metab. 1973, 36:207-214.
17. Siiteri P.K., MacDonald P.C. Placental estrogen biosynthesis during human pregnancy. J. Clin. Endocrinol. Metab. 1966, 26:751-761.
18. Simpson E.R. Role of aromatase in sex steroid action. J. Mol. Endocrinol. 2000, 25:149-156.
19. Gennari L., Nuti R., Bilezikian J.P. Aromatase activity and bone homeostasis in men. J. Clin. Endocrinol. Metab. 2004, 89:5898-5907.
20. de Ronde W., Pols H.A.P., van Leeuwen J.P.T.M., de Long F.H. The importance of estrogen in males. Clin. Endocrinol. 2003, 58:529-542.
21. Vedhuis J.D., Lizarralde G., Iranmanesh A. Divergent effects of short term glucocorticoid excess on the gonadotrophic and somatotrophic axis in normal men. J. Clin. Endocrinol. Metab. 1992, 74:96-102.
22. Bartsh W., Horst H.J., Becker H., Nehse G. Sex hormone binding globulin binding capacity, testosterone, 5α-dihydrotestosterone, oestradiol and prolactin in plasma of patients with prostatic carcinoma under various types of hormonal treatment. Acta Endocrinol. 1977, 85:650-664.
23. Moorjani S., Dupont A., Labrie F., et al. Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, oestrogen and combination treatment with luteinizing hormone-releasing hormone agonist and flutamide. J. Clin. Endocrinol. Metab. 1988, 66:314-3122.
24. Simpson E., Jones M., Davis S., Rubin G. Do intracrine mechanisms regulate aromatase expression?. J. Steroid Biochem. Mol. Biol. 1999, 69:447-452.
25. Labrie F., Belanger A., Cusan L., Candas B. Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: intracrinology. J. Clin. Endocrinol. Metab. 1997, 82:2403-2409.
26. Bruch H.R., Wolf L., Budde R., Romalo G., Schweikert H.U. Androstenedione metabolism in cultured human osteoblast-like cells. J. Clin. Endocrinol. Metab. 1992, 75:101-105.
27. Tanaka S., Haji M., Nishi Y., Yanase T., Takayanagi R., Nawata H. Aromatase activity in human osteoblast-like osteosarcoma cell. Calcif. Tissue Int. 1993, 52:107-109.
28. Sasano H., Uzuki M., Sawai T., et al. Aromatase in human bone tissue. J. Bone Miner. Res. 1997, 12:1416-1423.
29. Schweikert H.-U., Wolf L., Romalo G. Oestrogen formation from androstenedione in human bone. Clin. Endocrinol. 1995, 43:37-42.
30. Hernández J.L., Garcés C.M., Sumillera M., et al. Aromatase expression in osteoarthritic and osteoporotic bone. Arthritis Rheum. 2008, 58:1696-1700.
31. Chen S.A., Besman M.J., Sparkes R.S., et al. Human aromatase: cDNA cloning, Southern blot analysis, and assignment of the gene to chromosome 15. DNA 1988, 7:27-38.
32. Sebastian S., Bulun S.E. A highly complex organization of the regulatory region of the human CYP19 (aromatase) gene revealed by the Human Genome Project. J. Clin. Endocrinol. Metab. 2001, 6:4600-4602.
33. Bulun S.E., Sebastian S., Takayama K., Suzuki T., Sasano H., Shozu M. The human cyp19 (aromatase P450) gene: update on physiologic roles and genomic organization of promoters. J. Steroid Biochem. Mol. Biol. 2003, 86:219-224.
34. Wang H., Li R., Hu Y. The alternative non-coding cxons 1 of aromatase (Cyp19) gene modulate gene expression in a post-transcriptional manner. Endocrinology 2009, 150:3301-3307.
35. Shozu M., Simpson E.R. Aromatase expression of human osteoblast-like cells. Mol. Cell. Endocrinol. 1998, 39:117-129.
36. Shozu M., Zhao Y., Bulun S.E., Simpson E.R. Multiple splicing events involved in regulation of human aromatase expression by a novel promoter, I.6. Endocrinology 1998, 139:1610-1617.
37. Watanabe M., Simpson E.R., Pathirage N., Nakajin S., Clyne C.D. Aromatase expression in the human fetal osteoblastic cell line SV-HFO. J. Mol. Endocrinol. 2004, 32:533-545.
38. Nawata H., Tanaka S., Tanaka S., et al. Aromatase in bone cell: association with osteoporosis in postmenopausal women. J. Steroid Biochem. Mol. Biol. 1995, 53:165-174.
39. Tanaka S., Haji M., Takayanagi R., Tanaka S., Sugioka Y., Nawata H. 1,25-Dihydroxyvitamin D3 enhances the enzymatic activity and expression of the messenger ribonucleic acid for aromatase cytochrome P450 synergistically with dexamethasone depending on the vitamin D receptor level in cultured human osteoblasts. Endocrinology 1996, 137:1860-1869.
40. Yanase T., Suzuki S., Goto K., et al. Aromatase in bone: roles of Vitamin D3 and androgens. J. Steroid Biochem. Mol. Biol. 2003, 86:393-397.
41. Jeong J.H., Jung Y.K., Kim H.J., et al. The gene for aromatase, a rate-limiting enzyme for local estrogen biosynthesis, is a downstream target gene of Runx2 in skeletal tissues. Mol. Cell. Biol. 2010, 30:2365-2375.
42. Harada N., Utsumi T., Takagi Y. Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesis. Proc. Natl. Acad. Sci. USA 1993, 90:11312-11316.
43. Sebastian S., Takayama K., Shozu M., Bulun S.E. Cloning and characterization of a novel endothelial promoter of the human CYP19 (aromatase P450) gene that is upregulated in breast cancer tissue. Mol. Endocrinol. 2002, 16:2243-2254.
44. Bulun S.E. Aromatase deficiency and estrogen resistance: from molecular genetics to clinic. Semin. Reprod. Med. 2000, 18:31-39.
45. Belgorosky A., Guercio G., Pepe C., Saraco N., Rivarola M.A. Genetic and clinical spectrum of aromatase deficiency in infancy, childhood and adolescence. Horm. Res. 2009, 72:321-330.
46. Mullis P.E., Yoshimura N., Kuhlmann B., Lippuner K., Jaeger P., Harada H. Aromatase deficiency in a female who is compound heterozygote for two new point mutations in the P450arom gene: impact of estrogens on hypergonadotropic hypogonadism, multicystic ovaries, and bone densitometry in childhood. J. Clin. Endocrinol. Metab. 1997, 82:1739-1745.
47. Rochira V., Carani C. Aromatase deficiency in men: a clinical perspective. Nat. Rev. Endocrinol. 2009, 5:559-568.
48. Morishima A., Grumbach M.M., Simpson E.R., Fisher C., Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J. Clin. Endocrinol. Metab. 1995, 80:3689-3698.
49. Carani C., Qin K., Simoni M., et al. Effect of testosterone and estradiol in a man with aromatase deficiency. N. Engl. J. Med. 1997, 337:91-95.
50. Deladoey J., Fluck C., Bex M., Yoshimur N., Harada N., Mullis P.E. Aromatase deficiency caused by a novel P450 arom gene mutation: impact of absent estrogen production on serum gonadotropin concentration in a boy. J. Clin. Endocrinol. Metab. 1999, 84:4050-4054.
51. Hermann B.L., Saller B., Janssen O.E., et al. Impact of estrogen replacement therapy in a male with congenital aromatase deficiency caused by a novel mutation in the CYP19 gene. J. Clin. Endocrinol. Metab. 2002, 87:5476-5484.
52. Herve M.H., Kottler M.L., Pura M. Human gene mutations. Gene symbol: CYP19. Disease: aromatase deficiency. Hum. Genet. 2004, 114:224.
53. Boullion R., Bex M., Vanderschueren D., Boonen S. Estrogen are essential for male pubertal periosteal expansion. J. Clin. Endocrinol. Metab. 2004, 89:6025-6029.
54. Maffei L., Murata Y., Rochira V., et al. Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate and estradiol treatment. J. Clin. Endocrinol. Metab. 2004, 89:61-70.
55. Maffei L., Rochira V., Zirilli L., et al. A novel compound heterozygous mutation of the aromatase gene in an adult man: reinforced evidence on the relationship between congenital oestrogen deficiency, adiposity and the metabolic syndrome. Clin. Endocrinol. 2007, 67:218-224.
56. Lanfranco F., Zirilli L., Baldi M., et al. A novel mutation in the human aromatase gene: insights on the relationship among serum estradiol, longitudinal growth and bone mineral density in an adult man under estrogen replacement treatment. Bone 2008, 43:628-635.
57. Smith E.P., Boyd J., Frank G.R., et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N. Engl. J. Med. 1994, 331:1056-1061.
58. Bilezikian J.P., Morishima A., Bell J., Grumbach M.M. Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N. Engl. J. Med. 1998, 339:599-603.
59. Rochira V., Faustini-Fustini M., Balestrieri A., Carani C. Estrogen replacement therapy in a man with congenital aromatase deficiency: effects of different doses of transdermal estradiol on bone mineral density and hormonal parameters. J. Clin. Endocrinol. Metab. 2000, 85:1841-1845.
60. Seeman E. Clinical review 137: sexual dimorphism in skeletal size, density, and strength. J. Clin. Endocrinol. Metab. 2001, 86:4576-4584.
61. Sundberg M., Gärdsell P., Johnell O., Ornstein E. S. I. Karlsson, Pubertal growth in the femoral neck is predominantly characterized by increased bone size and not by increased bone density: a 4-year longitudinal study. Osteoporos. Int. 2003, 14:548-558.
62. Seeman E. Pathogenesis of bone fragility in women and men. Lancet 2002, 359:1841-1850.
63. Rochira V., Zirilli L., Madeo B., et al. Skeletal effects of long-term estrogen and testosterone replacement treatment in a man with congenital aromatase deficiency: evidence of a priming effect of estrogen for sex steroids action on bone. Bone 2007, 40:1662-1668.
64. Fisher C.R., Graves K.H., Parlow A.F., Simpson E.R. Characterization of mice deficient in aromatase (ArKO) because of targeted disruption of the cyp19 gene. Proc. Natl. Acad. Sci. USA 1998, 95:6965-6970.
65. Honda S., Harada N., Ito S., Takagi Y., Maeda S. Disruption of sexual behaviour in male aromatase-deficient mice lacking exons 1 and 2 of the cyp 19 gene. Biochem. Biophys. Res. Commun. 1998, 252:445-449.
66. Toda K., Saibara T., Okada T., Onishi S., Shizuta Y. A loss of aggressive behaviour and its reinstantement by oestrogen in mice lacking the aromatase gene (Cyp 19). J. Endocrinol. 2001, 168:217-220.
67. Oz O.K., Hirasawa G., Lawson J., et al. Bone phenotype of the aromatase deficient mouse. J. Steroid Biochem. Mol. Biol. 2001, 79:49-59.
68. Oz O.K., Zerwekh J.E., Risher C., et al. Bone has a sexually dimorphic response to aromatase deficiency. J. Bone Miner. Res. 2000, 15:507-514.
69. Miyaura C., Toda K., Inada M., et al. Sex- and age-related response to aromatase deficiency in bone. Biochem. Biophys. Res. Commun. 2001, 280:1062-1068.
70. Jones M.E.E., McInnes K.J., Boon W.C., Simpson E.R. Estrogen and adiposity-utilizing models of aromatase deficiency to explore the relationship. J. Steroid Biochem. Mol. Biol. 2007, 106:3-7.
71. Vico L., Vanacker J.M. Sex hormones and their receptors in bone homeostasis: insights from genetically modified mouse models. Osteoporos. Int. 2010, 21:365-372.
72. Matsumoto C., Inada M., Toda K., Miyaura C. Estrogen and androgen play distinct roles in bone turnover in male mice before and after reaching sexual maturity. Bone 2006, 38:220-226.
73. Vanderschueren D., Van Herck E., De Coster R., Bouillon R. Aromatization of androgens is important for skeletal maintenance of aged male rats. Calcif. Tissue Int. 1996, 59:179-183.
74. Vanderschueren D., van Herck E., Nijs J., Ederveen A.G., De Coster R., Bouillon R. Aromatase inhibition impairs skeletal modeling and decreases bone mineral density in growing male rats. Endocrinology 1997, 138:2301-2307.
75. Vanderschueren D., Boonen S., Ederveen A.G.H., et al. Skeletal effects of estrogen deficiency induced by an aromatase inhibitor in an aged male rat model. Bone 2000, 27:611-617.
76. Venken K., De Gendt K., Boonen S., et al. Relative impact of androgen and estrogen receptor activation in the effects of androgens on trabecular and cortical bone in growing male mice: a study in the androgen receptor knockout mouse model. J. Bone Miner. Res. 2006, 21:576-585.
77. Slemenda C.W., Longcope C., Zhou L., Hui S.L., Peacock M., Johnston C.C. Sex steroids and bone mass in older men: positive associations with serum estrogens and negative associations with androgens. J. Clin. Invest. 1997, 100:1755-1759.
78. Greendale G.A., Edelstein S., Barrett-Connor E. Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo study. J. Bone Miner. Res. 1997, 12:1833-1843.
79. Khosla S., Melton L.J., Atkinson E.J., O'Fallon W.M., Klee G.G., Riggs B.L. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J. Clin. Endocrinol. Metab. 1998, 83:2266-2274.
80. Ongphiphadhanakul B., Rajatanavin R., Chanprasertyothin S., Piaseu N., Chailurkit L. Serum oestradiol and oestrogen-receptor gene polymorphism are associated with bone mineral density independently of serum testosterone in normal males. Clin. Endocrinol. (Oxford) 1998, 49:803-809.
81. Center J.R., Nguyen T.V., Sambrook P.N., Eisman J.A. Hormonal and biochemical parameters in the determination of osteoporosis in elderly men. J. Clin. Endocrinol. Metab. 1999, 84:3626-3635.
82. Amin S., Zhang Y., Sawin C.T., et al. Association of hypogonadism and estradiol levels with bone mineral density in elderly men from the Framingham Study. Ann. Intern. Med. 2000, 133:951-963.
83. Barrett-Connor E., Mueller J.E., von Muhlen D.G., Laughlin G.A., Schneider D.L., Sartoris D.J. Low levels of estradiol are associated with vertebral fractures in older men, but not women: the Rancho Bernardo Study. J. Clin. Endocrinol. Metab. 2000, 85:219-223.
84. Szulc P., Munoz B., Claustrat B., et al. Bioavailable estradiol may be an important determinant of osteoporosis in men. The MINOS study. J. Clin. Endocrinol. Metab. 2001, 86:192-199.
85. Khosla S., Melton L.J., Atkinson E.J., O'Fallon W.M. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J. Clin. Endocrinol. Metab. 2001, 86:3555-3561.
86. Gennari L., Merlotti D., Martini G., et al. Longitudinal association between sex hormone levels, bone loss, and bone turnover in elderly men. J. Clin. Endocrinol. Metab. 2003, 88:5327-5333.
87. Taxel P., Raisz L.G. The effect of estrogen therapy on older men with low bone mass. J. Bone Miner. Res. 1997, 12:S353.
88. Anderson F.H., Francis R.M., Peaston R.T., Wastell H.J. Androgen supplementation in eugonadal men with osteoporosis: effects of six months' treatment on markers of bone formation and resorption. J. Bone Miner. Res. 1997, 12:472-478.
89. Falahati-Nini A., Riggs B.L., Atkinson E.J., O'Fallon W.M., Eastell R., Khosla S. Relative contributions of testosterone versus estrogen in regulating bone resorption and formation in normal elderly men. J. Clin. Invest. 2000, 106:1553-1560.
90. Lian J.B., Stein G.S., Canalis E., Gehron Robey P., Boskey A.L. Bone formation: osteoblast lineage cells, growth factors, matrix proteins, and the mineralization process. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism 1999, 14-38. Lippincott Williams & Wilkins, Philadelphia. fourth ed. M.F. Favus (Ed.).
91. Manolagas S.C. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr. Rev. 2000, 21:115-137.
92. Orwoll E. Gender differences in the skeleton: osteoporosis. J. Women's Health 1995, 4:429-431.
93. Leder B.Z., LeBlanc K.M., Schoenfeld D.A., Eastell R., Finkelstein J.S. Differential effects of androgens and estrogens on bone turnover in normal men. J. Clin. Endocrinol. Metab. 2003, 88:204-210.
94. Stepan J.J., Lachman M., Zverina J., Pacovsky V., Baylink D.J. Castrated men exhibit bone loss. Effect of calcitonin treatment on biochemical indeces of bone remodeling. J. Clin. Endocrinol. Metab. 1989, 69:523-527.
95. Taxel P., Kennedy D.G., Fall P.M., Willard A.K., Clive J.M., Raisz L.G. The effect of aromatase inhibition on sex steroids, gonadotropins, and markers of bone turnover in older men. J. Clin. Endocrinol. Metab. 2001, 86:2869-2874.
96. Leder B.Z., Finkelstein J.S. Effect of aromatase inhibition on bone metabolism in elderly hypogonadal men. Osteoporos. Int. 2005, 16:1487-1494.
97. Burnett-Bowie S.M., Roupenian K.C., Dere M.E., Lee H., Leder B.Z. Effects of aromatase inhibition in hypogonadal older men: a randomized, double-blind, placebo-controlled trial. Clin. Endocrinol. Oxf. 2009, 70:116-123.
98. Burnett-Bowie S.A., McKay E.A., Lee H., Leder B.Z. Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels. J. Clin. Endocrinol. Metab. 2009, 94:4785-4792.
99. Wickman S., Kajantie E., Dunkel L. Effects of suppression of estrogen action by the P450 aromatase inhibitor letrozole on bone mineral density and bone turnover in pubertal boys. J. Clin. Endocrinol. Metab. 2003, 88:3785-3793.
100. Rugo H.S. The breast cancer continuum in hormone-receptor positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors. Ann. Oncol. 2008, 19:16-27.
101. Riemsma R., Forbes C.A., Kessels A., Lykopoulos K., Amonkar M.M., Rea D.W., et al. Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer. Breast Cancer Res. Treat. 2010, 123(1):9-24. Epub Jun 10, 2010.
102. Bundred N.J. Aromatase inhibitors and bone health. Curr. Opin. Obstet. Gynecol. 2009 Feb, 21(1):60-67.
103. Pant S., Shapiro C.L. Aromatase inhibitor-associated bone loss: clinical considerations. Drugs 2008, 68:2591-2600.
104. Heshmati H.M., Khosla S., Robins S.P., O'Fallon W.M., Melton L.J., Riggs B.L. Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. J. Bone Miner. Res. 2002, 17:172-178.
105. Ponzone R., Mininanni P., Cassina E., Pastorino F., Sismondi P. Aromatase inhibitors for breast cancer: different structures, same effects?. Endocr. Relat. Cancer 2008, 15:27-36.
106. Howell A., Cuzick J., Baum M., et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005, 365:60-62.
107. Eastell R., Adams J.E., Coleman R.E., et al. Effect of anastrozole on bone mineral density: 5-year results from the Anastrozole, Tamoxifen, Alone or in Combination Trial 18233230. J. Clin. Oncol. 2008, 26:1051-1057.
108. Coates A.S., Keshaviah A., Thurlimann B., et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J. Clin. Oncol. 2007, 25:486-492.
109. Ghazi M., Roux C. Hormonal deprivation therapy-induced osteoporosis in postmenopausal women with breast cancer. Best Pract. Res. Clin. Rheumatol. 2009, 23:805-811.
110. Goss P.E., Ingle J.N., Martino S., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med. 2003, 349:1793-1802.
111. Perez E.A., Josse R.G., Pritchard K.I., et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA. 17. J. Clin. Oncol. 2006, 24:3629-3635.
112. Lønning P.E., Geisler J., Krag L.E., et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J. Clin. Oncol. 2005, 23:5126-5137.
113. Coombes R.C., Hall E., Gibson L.J., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med. 2004, 350:1081-1092.
114. Coleman R.E., Banks L.M., Girgis S.I., et al. Skeletal effects of exemestane on bone-mineral density, bone, biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol. 2007, 8:119-127.
115. Hadji P. Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Crit. Rev. Oncol. Hematol. 2009, 69:73-82.
116. Hillner B.E., Ingle J.N., Chlebowski R.T., et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J. Clin. Oncol. 2003, 21:4042-4057.
117. Reid D.M. Prevention of osteoporosis after breast cancer. Maturitas 2009, 64:4-8.
118. Rozenberg S., Carly B., Liebens F., Antoine C. Risks of osteoporosis associated with breast cancer treatment: the need to access to preventive treatment. Maturitas 2009, 64:1-3.
119. Bulun S.E., Lin Z., Zhao H., et al. Regulation of aromatase expression in breast cancer tissue. Ann. NY Acad. Sci. 2009, 1155:121-131.
120. Hiscox S., Barrett-Lee P., Borley A.C., Nicholson R.I. Combining Src inhibitors and aromatase inhibitors: a novel strategy for overcoming endocrine resistance and bone loss. Eur. J. Cancer 2010, 46:2187-2195.
121. Krishnan A.V., Swami S., Peng L., Wang J., Moreno J., Feldman D. Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy. Endocrinology 2010, 151:32-42.
122. Stratakis C.A., Vottero A., Brodie A., et al. The aromatase excess syndrome is associated with feminization of both sexes and autosomal dominant transmission of aberrant P450 aromatase gene transcription. J. Clin. Endocrinol. Metab. 1998, 83:1348-1357.
123. Shozu M., Sebastian S., Takayama K., et al. Estrogen excess associated with novel gain-of-function mutations affecting the aromatase gene. N. Engl. J. Med. 2003, 348:1855-1865.
124. Demura M., Martin R.M., Shozu M., et al. Regional rearrangements in chromosome 15q21 cause formation of cryptic promoters for the CYP19 (aromatase) gene. Hum. Mol. Genet. 2007, 16:2529-2541.
125. Martin R.M., Lin C.J., Nishi M.Y., et al. Familial hyperestrogenism in both sexes: clinical, hormonal, and molecular studies of two siblings. J. Clin. Endocrinol. Metab. 2003, 88:3027-3034.
126. Peng Z., Li X., Makela S., Vaananen H.K., Poutanen M. Skeletal changes in transgenic male mice expressing human cytochrome p450 aromatase. J. Bone Miner. Res. 2004, 19:1320-1328.
127. Sjogren K., Lagerquist M., Moverare-Skrtic S., et al. Elevated aromatase expression in osteoblasts leads to increased bone mass without systemic adverse effects. J. Bone Miner. Res. 2009, 24:1263-1270.
128. Doran P.M., Riggs B.L., Atkinson E.J., Khosla S. Effects of raloxifene, a selective estrogen receptor modulator, on bone turnover markers and serum sex steroid and lipid levels in elderly men. J. Bone Miner. Res. 2001, 16:2118-2125.
129. Khosla S., Melton L.J., Robb R.A., et al. Relationship of volumetric BMD and structural parameters at different skeletal sites to sex steroid levels in men. J. Bone Miner. Res. 2005, 20:730-740.
130. Khosla S., Riggs B.L., Robb R.A., et al. Relationship of volumetric bone density and structural parameters at different skeletal sites to sex steroid levels in women. J. Clin. Endocrinol. Metab. 2005, 90:5096-5103.
131. Mellström D., Vandenput L., Mallmin H., et al. Older men with low serum estradiol and high serum SHBG have an increased risk of fractures. J. Bone Miner. Res. 2008, 23:1552-1560.
132. Simpson E., Rubin G., Clyne C., et al. The role of local estrogen biosynthesis in males and females. Trends Endocrinol. Metab. 2000, 11:184-188.
133. Labrie F., Belanger A., Luu-The V., et al. DHEA and the intracrine formation of androgens and estrogens in peripheral target tissue: its role during aging. Steroids 1998, 63:322-328.
134. Siegelmann-Danieli N., Buetow K.H. Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk. Br. J. Cancer 1999, 79:456-463.
135. Kristensen V.N., Harada N., Yoshimura N., et al. Genetic variants of cyp19 (aromatase) and breast cancer. Oncogene 2000, 19:1329-1333.
136. Masi L., Becherini L., Gennari L., et al. Polymorphism of the aromatase gene in postmenopausal Italian women: distribution and correlation with bone mass and fracture risk. J. Clin. Endocrinol. Metab. 2001, 86:2263-2269.
137. Van Pottelbergh I., Goemaere S., Kaufman J.M. Bioavailable estradiol and aromatase gene polymorphism are determinants of bone mineral density changes in men over 70 years of age. J. Clin. Endocrinol. Metab. 2003, 88:3075-3081.
138. Gennari L., Masi L., Merlotti D., et al. A polymorphic CYP19 TTTA repeat influences aromatase activity and estrogen levels in elderly men: effects on bone metabolism. J. Clin. Endocrinol. Metab. 2004, 89:2803-2810.
139. Somner J., McLellan S., Cheung J., et al. Polymorphisms in the P450 c17 (17-hydroxylase/17, 20-lyase) and P450 c19 (aromatase) genes: association with serum sex steroid concentrations and bone mineral density in postmenopausal women. J. Clin. Endocrinol. Metab. 2004, 89:344-351.
140. Ahsan H., Whittemore A.S., Chen Y., et al. Variants in estrogen-biosynthesis genes CYP17 and CYP19 and breast cancer risk: a family-based genetic association study. Breast Cancer Res. 2005, 7:R71-R81.
141. Riancho J.A. Polymorphisms in the CYP19 gene that influence bone mineral density. Pharmacogenomics 2007, 8:339-352.
142. Talbott K.E., Gammon M.D., Kibriya M.G., et al. A CYP19 (aromatase) polymorphism is associated with increased premenopausal breast cancer risk. Breast Cancer Res. Treat. 2008, 111:481-487.
143. Yang H.P., Gonzalez Bosquet J., Li Q., et al. Common genetic variation in the sex hormone metabolic pathway and endometrial cancer risk: pathway-based evaluation of candidate genes. Carcinogenesis 2010, 31:827-833.
144. Eriksson A.L., Lorentzon M., Vandenput L., et al. Genetic variations in sex steroid-related genes as predictors of serum estrogen levels in men. J. Clin. Endocrinol. Metab. 2009, 94:1033-1041.
145. Setiawan V.W., Doherty J.A., Shu X.O., et al. Two estrogen-related variants in CYP19A1 and endometrial cancer risk: a pooled analysis in the Epidemiology of Endometrial Cancer Consortium. Cancer Epidemiol. Biomarkers Prev. 2009, 18:242-247.
146. Limer K.L., Pye S.R., Thomson W., et al. Genetic variation in sex hormone genes influences heel ultrasound parameters in middle-aged and elderly men: results from the European Male Aging Study (EMAS). J. Bone Miner. Res. 2009, 24:314-323.
147. Travis R.C., Schumacher F., Hirschhorn J.N., et al. CYP19A1 genetic variation in relation to prostate cancer risk and circulating sex hormone concentrations in men from the Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiol. Biomarkers Prev. 2009, 18:2734-2744.
148. Ma X., Qi X., Chen C., et al. Association between CYP19 polymorphisms and breast cancer risk: results from 10, 592 cases and 11, 720 controls. Breast Cancer Res. Treat. 2010, 122:495-501.
149. Remes T., Vaisanen S.B., Mahonen A., et al. Aerobic exercise and bone mineral density in middle-aged Finnish men: a controlled randomized trial with reference to androgen receptor, aromatase, and estrogen receptor α gene polymorphisms. Bone 2003, 32:412-420.
150. Lorentzon M., Swanson C., Eriksson A.L., Mellström D., Ohlsson C. Polymorphisms in the aromatase gene predict areal BMD as a result of affected cortical bone size: the GOOD study. J. Bone Miner. Res. 2006, 21:332-339.
151. Riancho J.A., Sañudo C., Valero C., et al. Association of the aromatase gene alleles with BMD: epidemiological and functional evidence. J. Bone Miner. Res. 2009, 24:1709-1718.
152. Yang S., Fang Z., Suzuki T., et al. Regulation of aromatase P450 expression in endometriotic and endometrial stromal cells by CCAAT/enhancer binding proteins (C/EBPs): decreased C/EBPbeta in endometriosis is associated with overexpression of aromatase. J. Clin. Endocrinol. Metab. 2002, 87:2336-2345.
153. Ishikawa H., Fencki V., Marsh E.E., et al. CCAAT/enhancer binding protein beta regulates aromatase expression via multiple and novel cis-regulatory sequences in uterine leiomyoma. J. Clin. Endocrinol. Metab. 2008, 93:981-991.
154. Demura M., Bulun S.E. CpG dinucleotide methylation of the CYP19 I.3/II promoter modulates cAMP-stimulated aromatase activity. Mol. Cell. Endocrinol. 2008, 283:127-132.
155. Yanase T., Mu Y.M., Nishi Y., et al. Regulation of aromatase by nuclear receptors. J. Steroid Biochem. Mol. Biol. 2001, 79:187-192.
156. Mu Y.M., Yanase T., Nishi Y., Takayanagi R., Goto K., Nawata H. Combined treatment with specific ligands for PPARgamma:RXR nuclear receptor system markedly inhibits the expression of cytochrome P450arom in human granulosa cancer cells. Mol. Cell. Endocrinol. 2001, 181:239-248.
157. Mu Y.M., Yanase T., Nishi Y., et al. Insulin sensitizer, troglitazone, directly inhibits aromatase activity in human ovarian granulosa cells. Biochem. Biophys. Res. Commun. 2000, 271:710-713.
158. Lovekamp-Swan T., Jetten A.M., Davis B.J. Dual activation of PPARalpha and PPARgamma by mono-(2-ethylhexyl) phthalate in rat ovarian granulosa cells. Mol. Cell. Endocrinol. 2003, 201:133-141.
159. Toda K., Okada T., Miyaura C., Saibara T. Fenofibrate, a ligand for PPARγ, inhibits aromatase cytocrome P450 expression in the ovary of mouse. J. Lipid Res. 2003, 44:265-270.
160. Gasnier C., Dumont C., Benachour N., Clair E., Chagnon M.C., Séralini G.E. Glyphosate-based herbicides are toxic and endocrine disruptors in human cell lines. Toxicology 2009, 262:184-191.
161. Harris R.E., Alshafie G.A., Abou-Issa H., Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res. 2000, 60:2101-2103.
162. Abou-Issa H.M., Alshafie G.A., Seibert K., Koki A.T., Masferrer J.L., Harris R.E. Dose-response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis. Anticancer Res. 2001, 21:3425-3432.
163. Raisz L. Physiologic and pathologic roles of prostaglandins and other eicosanoids in bone metabolism. J. Nutr. 1995, 125:2024S-2027S.
164. Carbone L., Tylavsky F.A., Cauley J.A., et al. Association between bone mineral density and the use of nonsteroidal anti-inflammatory drugs and aspirin: impact of cyclooxygenase selectivity. J. Bone Miner. Res. 2003, 18:1795-1802.
165. Eng E.T., Ye J.J., Williams D., et al. Suppression of estrogen biosynthesis by procyanidin dimers in red wine and grape seeds. Cancer Res. 2003, 63:8516-8522.
166. Doering I.L., Richter E. Inhibition of human aromatase by myosmine. Drug Metab. Lett. 2009, 3:83-86.
167. Takayanagi R., Goto K., Suzuki S., Tanaka S., Shimoda S., Nawata H. Dehydroepiandrosterone (DHEA) as a possible source for estrogen formation in bone cells: correlation between bone mineral density and serum DHEA-sulfate concentration in postmenopausal women, and the presence of aromatase to be enhanced by 1,25-dihydroxyvitamin D3 in human osteoblasts. Mech. Ageing Dev. 2002, 123:1107-1114.
168. Tanaka S., Haji M., Takayanagi R., Nawata H. 1,25-Dihydroxyvitamin D3 enhances the enzymatic activity and expression of the messenger ribonucleic acid for aromatase cytochrome P450 synergistically with dexamethasone depending on the vitamin D receptor level in cultured human osteoblasts. Endocrinology 1996, 137:1860-1869.
169. Kinuta K., Tanaka H., Moriwake T., Aya K., Kato S., Seino Y. Vitamin D is an important factor in estrogen biosynthesis of both female and male gonads. Endocrinology 2000, 141:1317-1324.
170. Bulun S.E., Noble L.S., Takayama K., et al. Endocrine disorders associated with inappropriately high aromatase expression. J. Steroid Biochem. Mol. Biol. 1997, 61:133-139.
171. Young J., Bulun S.E., Agarwal V., et al. Aromatase expression in a feminizing adrenocortical tumor. J. Clin. Endocrinol. Metab. 1996, 81:3173-3176.
172. Aiginger P., Kolbe H., Kuhbock J., Spona J., Geyer G. The endocrinology of testicular germinal cell tumors. Acta Endocrinol. 1981, 97:419-426.
173. Gordon G.G., Olivo J., Rafil F., Southren A.L. Conversion of androgens to estrogens in cirrhosis of the liver. J. Clin. Endocrinol. Metab. 1975, 40:1018-1026.
174. Longcope C., Pratt J.H., Finenberg E. Oestrogen and androgen dynamics in liver disease. J. Endocrinol. Invest. 1984, 7:629-634.
175. Figura N., Gennari L., Merlotti D., et al. Helicobacter pylori infection in male patients with osteoporosis and controls. Dig. Dis. Sci. 2005, 50:847-852.
176. Ueyama T., Shirasawa N., Numazawa M., et al. Gastric parietal cells: potent endocrine role in secreting estrogen as a possible regulator of gastro-hepatic axis. Endocrinology 2002, 143:3162-3170.
177. Burul-Bozkurt N., Pekiner C., Kelicen P. Diabetes alters aromatase enzyme levels in gonadal tissues of rats. Naunyn Schmiedebergs Arch. Pharmacol. 2010, 382:33-41.
178. Prabhu A., Xu Q., Manigrasso M.B., et al. Expression of aromatase, androgen and estrogen receptors in peripheral target tissues in diabetes. Steroids 2010, 75:779-787.
179. Brown K.A., Hunger N.I., Docanto M., Simpson E.R. Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase. Breast Cancer Res. Treat. 2010, 123:591-596.
180. Rice S., Pellatt L., Ramanathan K., Whitehead S.A., Mason H.D. Metformin inhibits aromatase via an extracellular signal-regulated kinase-mediated pathway. Endocrinology 2009, 150:4794-4801.